Novel Microdevices specializes in advanced medical diagnostic technologies, particularly focusing on a high-performance, point-of-care RT-PCR platform. This innovative system is capable of rapidly detecting respiratory viruses such as RSV, Influenza A, Influenza B, and COVID-19 within just 15 minutes. The device is designed for portability, weighing only four pounds and operating on battery power, making it ideal for use in low-resource settings and low- and middle-income countries. The platform utilizes polymerase chain reaction (PCR) technology through a disposable cartridge, allowing for the analysis of genetic sequences to identify diseases and antibiotic resistance mutations.

The Novel Dx system employs Nucleic Acid Amplification Techniques (NAAT) to deliver lab-quality results in under 15 minutes, enabling immediate testing, diagnosis, and treatment during a single patient visit. Its features include high sensitivity for detecting low levels of pathogens, a user-friendly automated design suitable for CLIA waiver, and the ability to multiplex multiple targets per test. Additionally, the system is connected to the Novel Dx Cloud for enhanced data management and throughput, all while maintaining affordability with low costs for instruments and cartridges.

United States

Lab-quality, Clinically Actionable Results in Minutes Anywhere!

    Novel Dx detects the genetic material of pathogens using Nucleic Acid Amplification techniques. These are the same methods that are utilized in large reference laboratories
    Novel Dx delivers lab-quality results in under 30 minutes so patients can be tested and treated in the same visit

Novel Microdevices

Company Details